Key result
Sustained release verapamil was more effective than hydrochlorothiazide in achieving target diastolic blood pressure at 8 weeks (58% vs 43%) and at 48 weeks without combination therapy (45% vs 25%).
Why the study?
Does sustained release verapamil improve achievement of target diastolic blood pressure compared to hydrochlorothiazide in patients with mild to moderate hypertension?
Population
369 patients with mild to moderate hypertension
Comparison
Sustained release verapamil 120 mg once daily… vs Hydrochlorothiazide 12.5 mg once daily, titrated…
Design
RCT, Randomised, Double blind comparison for single drug, followed by open…
Follow-up
48 weeks
Authors
Loading...
Supports verapamil SR over hydrochlorothiazide for initial monotherapy in mild-moderate hypertension; extends RCT evidence for calcium channel blockers as first-line agents.
RCT (n=369)
Double-blind
Randomized
Yes
Does sustained release verapamil improve achievement of target diastolic blood pressure compared to hydrochlorothiazide in patients with mild to moderate hypertension?
Absolute Event Rate: 58% vs 43%
Sustained release verapamil was more effective than hydrochlorothiazide as monotherapy and in combination for achieving target diastolic blood pressure in patients with mild to moderate hypertension.
Holzgreve et al. (1989) conducted an RCT in Mild to moderate hypertension (n=369). Sustained release verapamil vs. Hydrochlorothiazide was evaluated on Achievement of target diastolic blood pressure (<90 mm Hg) at 8 weeks. Sustained release verapamil was more effective than hydrochlorothiazide in achieving target diastolic blood pressure at 8 weeks (58% vs 43%) and at 48 weeks without combination therapy (45% vs 25%).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: